Management Heart Failure with Preserved Ejection Fraction: A Mini Review

Main Article Content

Sidhi Laksono
Robby Franata


BACKGROUND: Heart failure (HF) is a complex clinical syndrome that results when heart’s ability to contract or fill is impaired structurally or functionally. Current guideline has been classified HF according to level of left ventricular ejection fraction (EF). 1) Heart failure with reduced ejection fraction (HRrEF): EF ≤ 40%; 2) Heart failure with mildy ejection fraction (HRmrEF): EF 41 - 49%; 3) Heart failure with preserved ejection fraction (HRpEF): EF ≥50%.

AIM: We aimed to analyse the management of heart failure with preserved ejection fraction.

METHODS: We conducted a literature search of relevant articles in various databases (Pubmed & Google Scholar). Articles to include in the review was based on agreement of the authors.

RESULTS: Heart failure with preserved ejection fraction (HFpEF) accounts for 50% of all heart failure cases. HFpEF remains a challenging condition to diagnose given its unclear and often heterogenous etiology with numerous clinical mimics and complex systemic pathophysiology.

CONCLUSION: Additionally, effective treatment modalities are limited with numerous negative clinical trials over the past few decades. In this review, we updated the last knowledge of management HFpEF by reviewing recent guideline and studies.


Download data is not yet available.

Article Details

How to Cite
Laksono S, Franata R. Management Heart Failure with Preserved Ejection Fraction: A Mini Review. SEE J Cardiol [Internet]. 2023 Aug. 21 [cited 2023 Dec. 2];4(1):52-7. Available from:
General Cardiology


Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol.

;14(10):591-602. PMid:28492288

Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: A report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352-80. PMid:33605000

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. PMid:34447992

Van Aelst LN, Arrigo M, Placido R, Akiyama E, Girerd N, Zannad F, et al. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion. Eur J Heart Fail. 2018;20(4):738-47. PMid:29251818

Omote K, Verbrugge FH, Sorimachi H, Omar M, Popovic D, Obokata M, et al. Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea. Eur J Heart Fail. 2022;387(12):1089-98. PMid:36420788

Kumar AA, Gupta DK. Heart failure with preserved ejection fraction. In: Hayes KM, Dellise NR, editors. Managing Heart Failure in Primary Care: A Case Study Approach. Cham: Springer; 2023.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. AHA/ACC/HFSA Guideline for the management of heart failure: A report of the American college of cardiology/ American heart association joint committee on clinical practice guidelines. Circulation. 2022;145:895-1032.

Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81(18):1810-34. PMid:37137592

Desai AS, Lam CS, McMurray JJ, Redfield MM. How to manage heart failure with preserved ejection fraction: Practical guidance for clinicians. JACC Heart Fail. 2023;11(6):619-36. PMid:37140514

Hibodeau JT, Turer AT, Gualano SK, Ayers CR, Velez- Martinez M, Mishkin JD, et al. Characterization of a novel symptom of advanced heart failure: Bendopnea. JACC Heart Fail. 2014;2(1):24-31. PMid:24622115

Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction. JAMA 2023;329(10):827-38. PMid:36917048

Reddy YN, Kaye DM, Handoko ML, van de Bovenkamp AA, Tedford RJ, Keck C, et al. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea. JAMA Cardiol. 2022;7(9):891-9. PMid:35830183

Jain CC, Borlaug BA. Performance and interpretation of invasive hemodynamic exercise testing. Chest. 2020;158(5):2119-29. PMid:32473950

Solomon SD, Rizkala AR, Lefkowitz MP, Shi VC, Gong JJ, Anavekar N, et al. Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial. Circ Heart Fail. 2018;11(7):e004962. PMid:29980595

Costanzo MR, Stevenson LW, Adamson PB, Desai AS, Heywood JT, Bourge RC, et al. Interventions linked to decreased heart failure hospitalizations during ambulatory pulmonary artery pressure monitoring. J Am Coll Cardiol Heart Fail. 2016;4(5):333-44. PMid:26874388

Teramoto K, Teng TH, Chandramouli C, Tromp J, Sakata Y, Lam CS. Epidemiology and clinical features of heart failure with preserved ejection fraction. Card Fail Rev. 2022;8:e27. PMid:35991117

Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71. PMid:23684677

Kawano H, Fuiwara A, Kai H, Kumagai E, Okamoto R, Shibata R, et al. Effects of blood pressure lowering in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis. Hypertens Res. 2019;42(4):504-13. PMid:30948821

Kristensen SL, Jhund PS, Lee MM, Køber L, Solomon SD, Granger CB, et al. Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovasc Drugs Ther. 2017;31(5-6):545-9. PMid:28948430

Lam CS. Diabetic cardiomyopathy: An expression of stage B heart failure with preserved ejection fraction. Diab Vasc Dis Res.

;12(4):234-8. PMid:25908570

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451-61. PMid:34449189

Kitzman DW, Brubaker P, Morgan T, Haykowsky M, Hundley G, Kraus WE, et al. Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: A randomized clinical trial. JAMA. 2016;315(1):36-46. PMid:26746456

Kitzman DW, Whellan DJ, Duncan P, Pastva AM, Mentz RJ, Reeves GR, et al. Physical rehabilitation for older patients hospitalized for heart failure. N Engl J Med. 2021;385(3):203216.

Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13(1):18-28. PMid:20685685

Vaduganathan M, Piccini JP, Camm AJ, Crijns HJ, Anker SD, Butler J, et al. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: A post-hoc analysis of the ATHENA trial. Eur J Heart Fail. 2022;24(6):1094-101. PMid:35293087

Packer DL, Piccini JP, Monahan KH, Al-Khalidi HR, Silverstein AP, Noseworthy PA, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: Results from the CABANA trial. Circulation. 2021;143(14):1377-90. PMid:33554614

Vaduganathan M, Docherty DF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022;400(10354):757-67. PMid:36041474

Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-98. PMid:36027570

Solomon SD, McMurray JJ,Anand IS, Ge J, Lam CS, MaggioniAP, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609-20. PMid:31475794

Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation 2020;141(5):352-61. PMid:31736342

Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosteroneantagonist(TOPCAT)trial.Circulation.2015;131(1):34-42. PMid:25406305

Solomon SD, Claggett B, Lewis EF, Desai A, Anand I, Sweitzer NK, et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J. 2016;37(5):455-62. PMid:26374849